This HTML5 document contains 99 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n11http://linked.opendata.cz/resource/drugbank/drug/DB00746/identifier/pubchem-substance/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n14http://linked.opendata.cz/resource/drugbank/drug/DB00746/identifier/kegg-drug/
n27http://linked.opendata.cz/resource/AHFS/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00746/identifier/drugbank/
foafhttp://xmlns.com/foaf/0.1/
n29http://linked.opendata.cz/resource/mesh/concept/
n8http://linked.opendata.cz/resource/drugbank/company/
n6http://linked.opendata.cz/resource/drugbank/dosage/
n12http://linked.opendata.cz/resource/drugbank/drug/DB00746/identifier/national-drug-code-directory/
n26http://bio2rdf.org/drugbank:
n25http://linked.opendata.cz/resource/drugbank/drug/DB00746/identifier/chemspider/
admshttp://www.w3.org/ns/adms#
n24http://linked.opendata.cz/resource/drugbank/drug/DB00746/identifier/chebi/
n21http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n22http://linked.opendata.cz/resource/drugbank/drug/DB00746/identifier/wikipedia/
n5http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n28http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00746/identifier/pharmgkb/
n18http://www.drugs.com/cdi/
n4http://linked.opendata.cz/resource/drugbank/property/
n13http://linked.opendata.cz/resource/drugbank/drug/DB00746/identifier/kegg-compound/
xsdhhttp://www.w3.org/2001/XMLSchema#
n10http://linked.opendata.cz/resource/drugbank/drug/DB00746/identifier/pubchem-compound/
n16http://linked.opendata.cz/resource/atc/
n15http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00746
rdf:type
n3:Drug
n3:description
Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form. [PubChem]
n3:dosage
n6:271B5638-363D-11E5-9242-09173F13E4C5 n6:271B5639-363D-11E5-9242-09173F13E4C5 n6:271B563A-363D-11E5-9242-09173F13E4C5 n6:271B563B-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# "Link":http://www.nlm.nih.gov/medlineplus/druginfo/uspdi/203185.html
n3:group
approved investigational
n3:halfLife
Biphasic elimination pattern in healthy volunteers with a first rapid phase half life of 1 hour and a second slow phase half-life of 6 hours.
n3:indication
Used to treat acute iron or aluminum toxicity (an excess of aluminum in the body) in certain patients. Also used in certain patients with anemia who must receive many blood transfusions.
n3:manufacturer
n8:271B562D-363D-11E5-9242-09173F13E4C5 n8:271B562E-363D-11E5-9242-09173F13E4C5 n8:271B562B-363D-11E5-9242-09173F13E4C5 n8:271B562C-363D-11E5-9242-09173F13E4C5 n8:271B562A-363D-11E5-9242-09173F13E4C5
owl:sameAs
n21:DB00746 n26:DB00746
dcterms:title
Deferoxamine
adms:identifier
n10:2973 n11:46506395 n12:0409-2336-10 n13:C06940 n14:D03670 n19:PA164746490 n22:Deferoxamine n23:DB00746 n24:4356 n25:2867
n3:mechanismOfAction
Deferoxamine works in treating iron toxicity by binding trivalent (ferric) iron (for which it has a strong affinity), forming ferrioxamine, a stable complex which is eliminated via the kidneys. 100 mg of deferoxamine is capable of binding approximately 8.5 mg of trivalent (ferric) iron. Deferoxamine works in treating aluminum toxicity by binding to tissue-bound aluminum to form aluminoxamine, a stable, water-soluble complex. The formation of aluminoxamine increases blood concentrations of aluminum, resulting in an increased concentration gradient between the blood and dialysate, boosting the removal of aluminum during dialysis. 100 mg of deferoxamine is capable of binding approximately 4.1 mg of aluminum.
n3:packager
n8:271B5622-363D-11E5-9242-09173F13E4C5 n8:271B5623-363D-11E5-9242-09173F13E4C5 n8:271B5624-363D-11E5-9242-09173F13E4C5 n8:271B5625-363D-11E5-9242-09173F13E4C5 n8:271B5627-363D-11E5-9242-09173F13E4C5 n8:271B5628-363D-11E5-9242-09173F13E4C5 n8:271B5626-363D-11E5-9242-09173F13E4C5 n8:271B5629-363D-11E5-9242-09173F13E4C5
n3:routeOfElimination
Deferoxamine mesylate is metabolized principally by plasma enzymes, but the pathways have not yet been defined. Some is also excreted in the feces via the bile.
n3:synonym
Déferoxamine Desferrioxamine Deferoxamin Deferrioxamine b DFOA Deferoxaminum Deferoxamina DFO Deferrioxamine DFOM
n3:toxicity
Intravenous LD<sub>50</sub> in mouse, rat, and rabbit is 340 mg/kg, 520 mg/kg, and 600 mg/kg, respectively. Subcutaneous LD<sub>50</sub> in mouse and rat is 1600 mg/kg and >1000 mg/kg, respectively. Oral LD<sub>50</sub> in mouse and rat is >3000 mg/kg and >1000 mg/kg, respectively. Nephrotoxicity, ototoxicity and retinal toxicity have been reported following long-term administration for chronic iron overload.
n15:hasAHFSCode
n27:64-00-00
n3:proteinBinding
Less than 10% bound to serum proteins <i>in vitro</i>.
n3:salt
n3:synthesisReference
Zoltan Konyari, Vilmos Keri, Antal Kovacs, Sandor Horkay, Laszlo Eszenyi, Janos Erdelyi, Ilona Himesi, Gyorgy Toth, Janos Balint, SzilaJudit, Ferenc Vinczi, Csaba Szabo, Nelli Sas, "Process for the preparation of high-purity deferoxamine salts." U.S. Patent US5374771, issued July, 1965.
n28:hasConcept
n29:M0005750
foaf:page
n18:deferoxamine.html
n3:IUPAC-Name
n4:271B5640-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B5646-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B5645-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B5642-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B5643-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B5644-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B5656-363D-11E5-9242-09173F13E4C5 n4:271B563E-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B563F-363D-11E5-9242-09173F13E4C5 n4:271B563C-363D-11E5-9242-09173F13E4C5 n4:271B5658-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B563D-363D-11E5-9242-09173F13E4C5
n15:hasATCCode
n16:V03AC01
n3:H-Bond-Acceptor-Count
n4:271B564C-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B564D-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B5647-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B5648-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B564A-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B5649-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B564B-363D-11E5-9242-09173F13E4C5
n3:absorption
Deferoxamine is rapidly absorbed after intramuscular or subcutaneous administration, but only poorly absorbed from the gastrointestinal tract in the presence of intact mucosa.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
70-51-9
n3:category
n3:containedIn
n5:271B5636-363D-11E5-9242-09173F13E4C5 n5:271B5637-363D-11E5-9242-09173F13E4C5 n5:271B5634-363D-11E5-9242-09173F13E4C5 n5:271B5635-363D-11E5-9242-09173F13E4C5 n5:271B562F-363D-11E5-9242-09173F13E4C5 n5:271B5632-363D-11E5-9242-09173F13E4C5 n5:271B5633-363D-11E5-9242-09173F13E4C5 n5:271B5630-363D-11E5-9242-09173F13E4C5 n5:271B5631-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B5652-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B5654-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B5655-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B5657-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B5651-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B5650-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B5653-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B5641-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B564E-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B564F-363D-11E5-9242-09173F13E4C5